Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis
NCT ID: NCT02195258
Last Updated: 2014-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
95 participants
OBSERVATIONAL
2010-11-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma
NCT03592212
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
NCT02126839
Montelukast With Status Asthmaticus, Ages 2-5
NCT00491790
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
NCT02127697
Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth
NCT02013076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
salbutamol
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 6-16 years old
* asthmatic patients
* consulting for an exacerbation in a pediatric emergency department
* parental informed consent
Exclusion Criteria
* peak flow no available
* pneumonia
6 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital Necker-Enfants Malades
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helene Chappuy
MD Ph D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hélène Chappuy, MDPhD
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Necker Enfants Malades Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URC Paris centre
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.